Mutational-based medicine in breast cancer

dr. M. Balic, dr. C.W. Menke-van der Houven van Oordtenprof. dr. M.J. van de Vijver

In this Pharmacotherapy-Online special three specialists each highlight different aspects of new developments in breast cancer treatment.


Remarkable progress in sequencing technology over the past two decades has made it possible to profile tumors and identify clinically relevant genetic alterations. In breast cancer, the use of this technology has helped identifying key alterations in the PI3K pathway and PIK3CA gene which, in turn, have led to the development of several drugs targeting these alterations. In this Pharmacotherapy-Online Video Special on mutational-based medicine in breast cancer three specialists, Prof. dr. van de Vijver, Dr. Balic and Dr. Menke, each highlight different aspects of this new development in breast cancer treatment.


Deel de videospecial